Biosimilars – Forecast – Immunology

In 2022, sales of branded biologics in immunology exceeded $65 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this therapy area totaled approximately $3.9 billion. Throughout the 2022-2032 forecast period, increasing numbers of branded biologics in the immunology space are set to lose patent protection, and biosimilars will launch and reduce branded biologics’ patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.

Table of contents